📰 Nasdaq Cbay News
Page 2 - Nasdaq Cbay News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Cbay. Real-time updates on events, politics, business and more.
February 13, 2024
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) was downgraded by analysts at Raymond James from an “outperform” rating to a “market perform” rating in a research note issued to investors on Tuesday, Briefing.com reports. Several other equities analysts have also issued reports on the company. William Blair reaffirmed a “market perform” rating on shares of […]
February 10, 2024
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $25.72 and last traded at $24.89, with a volume of 549844 shares traded. The stock had previously closed at $24.00. Analyst Ratings Changes CBAY has been the subject […]
February 3, 2024
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) has received an average rating of “Buy” from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. Twelve analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target […]
January 9, 2024
Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) have been given a consensus recommendation of “Buy” by the thirteen ratings firms that are currently covering the company, MarketBeat reports. Twelve analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 […]
January 9, 2024
Emerald Mutual Fund Advisers Trust acquired a new position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 809,738 shares of the biopharmaceutical company’s stock, valued at approximately $12,073,000. Emerald Mutual Fund Advisers […]
December 19, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) insider Charles Mcwherter sold 11,332 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $21.48, for a total value of $243,411.36. Following the sale, the insider now directly owns 15,000 shares in the company, valued […]
December 16, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $21.98, for a total transaction of $109,900.00. The transaction was disclosed in a legal filing with the SEC, […]
November 20, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $17.38, for a total transaction of $86,900.00. The transaction was disclosed in a filing with the SEC, which […]
November 19, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) General Counsel Paul T. Quinlan sold 5,000 shares of CymaBay Therapeutics stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $17.38, for a total value of $86,900.00. The transaction was disclosed in a legal filing with the Securities & […]
November 18, 2023
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) insider Charles Mcwherter sold 11,342 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $18.28, for a total value of $207,331.76. Following the sale, the insider now directly owns 15,000 shares of the company’s […]